PBL Assay Science is excited to return to the 19th Annual WRIB (Workshop on Recent Issues in Bioanalysis) this April in New Orleans. Known for its scientific depth and cross-industry dialogue, WRIB is the ideal setting for high-quality conversations around biomarker strategy, assay development, and translational science.
While it’s been a few years since we last attended, we’ve always appreciated WRIB’s emphasis on substance over sales. As the industry increasingly focuses on strategic biomarker planning, qualification/validation, and selection, we’re excited to rejoin the conversation and share how our capabilities have evolved to meet today’s translational needs.
What PBL is Bringing to the Conversation
Since our last WRIB appearance, we’ve strengthened our biomarker capabilities, deepened our platform offerings, and refined how we support study teams from discovery to development.
Celebrating 35 Years of Science Innovation
2025 marks 35 years of assay development and product manufacturing at PBL. With over 278 years of combined experience and more than 9,000 product citations, our foundation reflects a longstanding commitment to scientific rigor, innovation, and flexibility.
New High-Sensitivity ELISA Kits for Translational Research
Our recently developed IL-22 and Total IL-15 human ELISA kits are designed for high-sensitivity applications in immuno-oncology, autoimmunity, and exploratory biomarker studies, enabling low-abundance detection in complex matrices.
Expanded Assay Capabilities Across Therapeutic Areas
We now support biomarker initiatives across neurodegeneration, immuno-oncology, autoimmune disorders, rare diseases, cardiovascular conditions, and more. Rather than working from predefined panels, our approach is collaborative and program-specific, aligning assay design with the scientific questions, sample limitations, and therapeutic program needs unique to each study.
Custom Assay Development, Qualification/Validation
In addition to our catalog of ELISA kits, proteins, and antibodies, PBL offers custom assay solutions with a client-focused mindset. We support fit-for-purpose qualification/validation strategies tailored to program goals, combining flexibility with deep scientific rigor to ensure performance is matched to study intent.
Biomarker Strategy Support That Drives Translational Impact
A strong biomarker strategy is essential for therapeutic development, particularly when it comes to pharmacodynamic assessment, patient stratification, endpoint relevance, and regulatory decision-making. PBL collaborates with clients to identify the most appropriate biomarkers for mechanism of action, build single or multi-biomarker strategies, and design robust study plans that yield meaningful, interpretable results. Our consultative approach brings together scientific insight and practical feasibility, aligning translational biomarker planning with the realities of clinical execution.
Meet the PBL Team at Booth 11
We’ll be exhibiting at Booth 11 with scientific expert Alok Pandey, PhD and business development executive Angela Stoyanovitch onsite. Whether you’re looking for high-quality ELISA kits, custom assay development, or deeper biomarker support for your program, we’d love to connect and learn more about your goals.
While we’ll be attending scientific sessions and soaking up the latest from our peers (especially in protein biomarkers), our priority is you. We’re actively booking meetings now—coffee chats, lunch conversations, or quick sit-downs to introduce our capabilities.
Don't wait--our schedule is filling quickly
Reach out now to reserve a time with our team: Book a Meeting with Us.
Ready to Chat?
Reach out today to schedule a meting with PBL at WRIB 2025, or stop by Booth 11 during exhibit hours (Tuesday-Thursday). Let's talk science, strategy, and solutions.